One Bio (OTCMKTS:ONBI) is a biotechnology company specializing in rapid microbial detection technologies and phage-based therapeutics. The company leverages advanced genomic sequencing and proprietary algorithms to identify and quantify pathogens in diverse sample types. It operates across multiple sectors, including agriculture, food safety, environmental monitoring, and human and animal health, offering end-to-end solutions for the detection and control of harmful microorganisms.
One Bio’s product portfolio centers on its PathoID platform, which delivers next-generation sequencing–based analysis for accurate and timely identification of bacteria, viruses, and fungi. Complementing this diagnostic capability, the company is building a pipeline of bacteriophage-based therapies that target specific bacterial strains, aiming to provide sustainable alternatives to traditional antibiotics and chemical antimicrobials. Through partnerships and service offerings, One Bio supports clients with custom testing, real-time monitoring, and tailored intervention strategies.
Since its inception, One Bio has grown its presence in North America and is expanding into European markets, collaborating with regulatory bodies and industry stakeholders to meet evolving safety and compliance requirements. The company’s management team includes professionals with backgrounds in microbiology, genomics, and biopharmaceutical development, guiding its strategic direction as it scales technologies for broader commercial adoption. One Bio began trading on the OTC Markets in 2023, marking a milestone in its efforts to democratize access to cutting-edge microbial solutions.
AI Generated. May Contain Errors.
